Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2003 2
2008 1
2010 1
2011 1
2012 1
2016 1
2017 2
2019 2
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Identification of CD133+/nestin+ putative cancer stem cells in non-small cell lung cancer.
Janikova M, Skarda J, Dziechciarkova M, Radova L, Chmelova J, Krejci V, Sedlakova E, Zapletalova J, Langova K, Klein J, Grygarkova I, Kolek V. Janikova M, et al. Among authors: grygarkova i. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Dec;154(4):321-6. doi: 10.5507/bp.2010.048. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010. PMID: 21293543
Sphingosine kinase-1 predicts overall survival outcomes in non-small cell lung cancer patients treated with carboplatin and navelbine.
Gachechiladze M, Tichý T, Kolek V, Grygárková I, Klein J, Mgebrishvili G, Kharaishvili G, Janíková M, Smičková P, Cierna L, Pitson S, Maddelein ML, Cuvillier O, Škarda J. Gachechiladze M, et al. Among authors: grygarkova i. Oncol Lett. 2019 Aug;18(2):1259-1266. doi: 10.3892/ol.2019.10447. Epub 2019 Jun 7. Oncol Lett. 2019. PMID: 31423186 Free PMC article.
Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.
Zatloukal P, Petruzelka L, Zemanová M, Kolek V, Skricková J, Pesek M, Fojtů H, Grygárková I, Sixtová D, Roubec J, Horenková E, Havel L, Průsa P, Nováková L, Skácel T, Kůta M. Zatloukal P, et al. Among authors: grygarkova i. Lung Cancer. 2003 Sep;41(3):321-31. doi: 10.1016/s0169-5002(03)00233-2. Lung Cancer. 2003. PMID: 12928123 Clinical Trial.
A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas.
Jancik S, Drabek J, Berkovcova J, Xu YZ, Stankova M, Klein J, Kolek V, Skarda J, Tichy T, Grygarkova I, Radzioch D, Hajduch M. Jancik S, et al. Among authors: grygarkova i. J Exp Clin Cancer Res. 2012 Sep 20;31(1):79. doi: 10.1186/1756-9966-31-79. J Exp Clin Cancer Res. 2012. PMID: 22995035 Free PMC article.
Long term follow-up of neoadjuvant-adjuvant combination treatment of IIIA stage non-small-cell-lung cancer: results of neoadjuvant carboplatin/vinorelbine and carboplatin/paclitaxel regimens combined with selective adjuvant chemotherapy according to in-vitro chemoresistance test.
Kolek V, Grygarkova I, Hajduch M, Klein J, Cwiertka K, Neoral C, Langova K, Mihal V. Kolek V, et al. Among authors: grygarkova i. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008 Dec;152(2):259-66. doi: 10.5507/bp.2008.040. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008. PMID: 19219217 Free article. Clinical Trial.
14 results